Appraising growth differentiation factor 15 as a promising biomarker in digestive system tumors: a meta-analysis

Wang, Yanqiu; Jiang, Tao; Jiang, Mingyan; Gu, Shuijing

doi:10.1186/s12885-019-5385-y

BMC Cancer

Table 2 Main features of all included studies used in the prognostic meta-analysis

From: Appraising growth differentiation factor 15 as a promising biomarker in digestive system tumors: a meta-analysis

Author & reference	Year	Country	Cancer type	Patient size	Sample type	Method	Expression level	HR	Survival point	P value	Follow-up time	extraction	Quartiles of GDF-15	NOS score
Li et al. [8]	2016	China	CRC	138	Serum	ELISA	Increased	1.915	OS	0.045	Unclear	Directly	/	6
Wang et al. [13]	2017	China	CRC	94	Serum	ELISA	Increased	2.917	TSS	0.0005	Average: 43 months	Directly	/	8
Wang et al. [13]	2017	China	CRC	94	Serum	ELISA	Increased	2.607	TSS	0.007	Average: 43 months	Directly	/	8
Wallin et al. [9]	2011	Sweden	CRC	320	Plasma	SP-PLA	Increased	2.11	OS	0.002	Median: 6 years	Directly	/	8
Brown et al. [10]	2003	Australia	CRC	261	Serum	ELISA	Increased	2.2	OS	0.0034	60 months	Directly	/	8
Mehta et al. [11]	2015	America	CRC	618	Plasma	ELISA	Increased	1.88	OS	< 0.0001	Median: 9.2 years	Directly	Quartile2	8
							Increased	1.77	OS	0.0002
							Increased	1.74	OS	0.0002
							Increased	1.94	CSS	0.003
							Increased	1.65	CSS	0.01
							Increased	1.67	CSS	0.009
							Increased	2.51	OS	< 0.0001			Quartile3
							Increased	2.55	OS	0.0002
							Increased	2.54	OS	0.0002
							Increased	2.64	CSS	0.003
							Increased	2.6	CSS	0.01
							Increased	2.67	CSS	0.009
							Increased	2.85	OS	< 0.0001			Quartile4
							Increased	2.63	OS	0.0002
							Increased	2.63	OS	0.0002
							Increased	2.73	CSS	0.003
							Increased	2.34	CSS	0.01
							Increased	2.4	CSS	0.009
Fisher et al. [22]	2015	Australia	EC	138	Plasma	ELISA	Increased	2.91	OS	0.076	60 months	Directly	/	9
Fisher et al. [22]	2015	Australia	EC	138	Plasma	ELISA	Increased	3.87	OS	0.048	60 months	Directly	/	9
Wang et al. [21]	2014	China	ESCC	286	Serum	ELISA	Increased	2.557	TSS	0.002	Average: 30 months	Directly	/	8
								2.625	TSS	0.005
								1.739	RFS	0.047
								1.789	RFS	0.050
Skipworth et al. [14]	2010	Australia	OGC	293	Plasma	ELISA	Increased	1.549	OS	0.036	Over 1500 days	Directly	/	8
Blanco-Calvo et al. [15]	2014	Spain	GC	52	Serum	ELISA	Increased	3.843	OS	0.001	Median:118.9 weeks	Directly	/	8
Blanco-Calvo et al. [15]	2014	Spain	GC	52	Serum	ELISA	Increased	3.608	PFS	< 0.001	Median:118.9 weeks	Directly	/	8

Abbreviations: OGC oesophago-gastric cancer, ESCC esophageal squamous cell carcinoma, GC Gastrointestinal cancer, EC esophageal carcinoma, OS overall survival, DFS disease-free survival, PFS progression-free survival, TSS tumor-specific survival, CSS cancer-specific survival, ELISA enzyme linked immunosorbent assay, NOS Newcastle-Ottawa Scale checklist, HR hazard ratio

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com